Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Changes in adipokines after transjugular intrahepatic porto-systemic shunt indicate an anabolic shift in metabolism.

Thomsen KL, Sandahl TD, Holland-Fischer P, Jessen N, Frystyk J, Flyvbjerg A, Grønbæk H, Vilstrup H.

Clin Nutr. 2012 Dec;31(6):940-5. doi: 10.1016/j.clnu.2012.04.001. Epub 2012 Apr 27.

PMID:
22541535
2.

TIPS implantation raises leptin levels in patients with liver cirrhosis.

Nolte W, Wirtz M, Rossbach C, Leonhardt U, Buchwald AB, Scholz KH, Ramadori G.

Exp Clin Endocrinol Diabetes. 2003 Oct;111(7):435-42.

PMID:
14614651
3.

Changes in body composition after transjugular intrahepatic portosystemic stent in cirrhosis: a critical review of literature.

Dasarathy J, Alkhouri N, Dasarathy S.

Liver Int. 2011 Oct;31(9):1250-8. doi: 10.1111/j.1478-3231.2011.02498.x. Epub 2011 Mar 8. Review.

PMID:
21745273
4.

Weight gain after transjugular intrahepatic portosystemic shunt is associated with improvement in body composition in malnourished patients with cirrhosis and hypermetabolism.

Plauth M, Schütz T, Buckendahl DP, Kreymann G, Pirlich M, Grüngreiff S, Romaniuk P, Ertl S, Weiss ML, Lochs H.

J Hepatol. 2004 Feb;40(2):228-33.

PMID:
14739092
5.

Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis.

Montomoli J, Holland-Fischer P, Bianchi G, Grønbaek H, Vilstrup H, Marchesini G, Zoli M.

World J Gastroenterol. 2010 Jan 21;16(3):348-53.

6.

Insulin sensitivity and body composition in cirrhosis: changes after TIPS.

Holland-Fischer P, Nielsen MF, Vilstrup H, Tønner-Nielsen D, Mengel A, Schmitz O, Grønbaek H.

Am J Physiol Gastrointest Liver Physiol. 2010 Aug;299(2):G486-93. doi: 10.1152/ajpgi.00375.2009. Epub 2010 May 20.

7.

Systemic and splanchnic endothelin-1 plasma levels in liver cirrhosis before and after transjugular intrahepatic portosystemic shunt (TIPS).

Nolte W, Ehrenreich H, Wiltfang J, Pahl K, Unterberg K, Kamrowski-Kruck H, Schindler CG, Figulla HR, Buchwald AB, Hartmann H, Ramadori G.

Liver. 2000 Feb;20(1):60-5.

PMID:
10726962
8.

The IGF system after insertion of a transjugular intrahepatic porto-systemic shunt in patients with liver cirrhosis.

Holland-Fischer P, Vilstrup H, Frystyk J, Nielsen DT, Flyvbjerg A, Grønbaek H.

Eur J Endocrinol. 2009 Jun;160(6):957-63. doi: 10.1530/EJE-08-0971. Epub 2009 Mar 31.

9.

Adipokines in Liver Cirrhosis.

Buechler C, Haberl EM, Rein-Fischboeck L, Aslanidis C.

Int J Mol Sci. 2017 Jun 29;18(7). pii: E1392. doi: 10.3390/ijms18071392. Review.

10.

Effect of transjugular intrahepatic portosystemic shunt on glycometabolism in cirrhosis patients.

Su AP, Cao SS, Le Tian B, Da Zhang Z, Hu WM, Zhang Y, Wang ZL, Babu SR, Hu T.

Clin Res Hepatol Gastroenterol. 2012 Feb;36(1):53-9. doi: 10.1016/j.clinre.2011.09.011. Epub 2011 Nov 17.

PMID:
22099870
11.

Splanchnic concentrations and postprandial release of visceral adipokines.

Wiest R, Moleda L, Farkas S, Scherer M, Kopp A, Wönckhaus U, Büchler C, Schölmerich J, Schäffler A.

Metabolism. 2010 May;59(5):664-70. doi: 10.1016/j.metabol.2009.09.011. Epub 2009 Nov 14.

PMID:
19913846
12.

Leptin, adiponectin, visfatin and retinol-binding protein-4 - mediators of comorbidities in patients with psoriasis?

Gerdes S, Osadtschy S, Rostami-Yazdi M, Buhles N, Weichenthal M, Mrowietz U.

Exp Dermatol. 2012 Jan;21(1):43-7. doi: 10.1111/j.1600-0625.2011.01402.x.

PMID:
22151390
13.

QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt.

Trevisani F, Merli M, Savelli F, Valeriano V, Zambruni A, Riggio O, Caraceni P, Domenicali M, Bernardi M.

J Hepatol. 2003 Apr;38(4):461-7.

PMID:
12663238
15.

Haemodynamic adaptation two months after transjugular intrahepatic portosystemic shunt (TIPS) in cirrhotic patients.

Colombato LA, Spahr L, Martinet JP, Dufresne MP, Lafortune M, Fenyves D, Pomier-Layrargues G.

Gut. 1996 Oct;39(4):600-4.

16.

Two-stage transjugular intrahepatic porta-systemic shunt for patients with cirrhosis and a high risk of portal-systemic encephalopathy patients as a bridge to orthotopic liver transplantation: a preliminary report.

Wróblewski T, Rowiński O, Ziarkiewicz-Wróblewska B, Górnicka B, Albrecht J, Jones EA, Krawczyk M.

Transplant Proc. 2006 Jan-Feb;38(1):204-8.

PMID:
16504703
17.

Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS).

Raddatz D, Rossbach C, Buchwald A, Scholz KH, Ramadori G, Nolte W.

Exp Clin Endocrinol Diabetes. 2005 May;113(5):268-74.

PMID:
15926112
18.

Prosthetic H-graft portacaval shunts vs transjugular intrahepatic portasystemic stent shunts: 18-year follow-up of a randomized trial.

Rosemurgy AS, Frohman HA, Teta AF, Luberice K, Ross SB.

J Am Coll Surg. 2012 Apr;214(4):445-53; discussion 453-5. doi: 10.1016/j.jamcollsurg.2011.12.042.

PMID:
22463885
19.

Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests.

Baron A, Gulberg V, Sauter G, Waggershauser T, Reiser M, Gerbes AL.

Hepatogastroenterology. 1998 Nov-Dec;45(24):2315-21.

PMID:
9951915
20.

Transjugular intrahepatic portosystemic shunt in five children with cystic fibrosis: long-term results.

Pozler O, Krajina A, Vanicek H, Hulek P, Zizka J, Michl A, Elias P.

Hepatogastroenterology. 2003 Jul-Aug;50(52):1111-4.

PMID:
12845992

Supplemental Content

Support Center